Vincent D de Jager, Wim Timens, Arnaud Bayle, Johan Botling, Luka Brcic, Reinhard Büttner, Maria Gabriela O Fernandes, Libor Havel, Maximilian J Hochmair, Paul Hofman, Annelies Janssens, Mikael Johansson, Léon van Kempen, Izidor Kern, Fernando Lopez-Rios, Margreet Lüchtenborg, José Carlos Machado, Katja Mohorcic, Luis Paz-Ares, Sanjay Popat, Aleš Ryška, Phillipe Taniere, Jürgen Wolf, Ed Schuuring, Anthonie J van der Wekken
In the past two decades, the treatment of metastatic non-small cell lung cancer (NSCLC), has undergone significant changes due to the introduction of targeted therapies and immunotherapy. These advancements have led to the need for predictive molecular tests to identify patients eligible for targeted therapy. This review provides an overview of the development and current application of targeted therapies and predictive biomarker testing in European patients with advanced stage NSCLC. Using data from eleven European countries, we conclude that recommendations for predictive testing are incorporated in national guidelines across Europe, although there are differences in their comprehensiveness...
March 2024: The Lancet regional health. Europe